• Mon news: Ventyx gets boost from Sanofi. PhRMA IRA legal challenge gets new life. AZ breast cancer drug disappoints. Teva’s once-monthly schizophrenia med. AZ gets FDA approval for first self-administered flu vaccine. See more on our front page

Biogen stock


<



Quite simple. The entire growth of the organization lies in a medication that has failed 20 other times in Alz. Biogen is convinced it will get approved, and frankly the fda could care less if it meets its primary endpoint. As long as the drug can show “anything” in the positive it will get approval.

Wall Street realizes everything hinges on 1 product. MS is dying a slow death, Tecfidera will erode like a beach under Hurricane Watch.

There’s your answer. Good day.
 




Quite simple. The entire growth of the organization lies in a medication that has failed 20 other times in Alz. Biogen is convinced it will get approved, and frankly the fda could care less if it meets its primary endpoint. As long as the drug can show “anything” in the positive it will get approval.

Wall Street realizes everything hinges on 1 product. MS is dying a slow death, Tecfidera will erode like a beach under Hurricane Watch.

There’s your answer. Good day.

I said good day!